An Official Website of the United States Government
Company Information:
Name:
RXGEN, INC.
Address:
100 DEEPWOOD DRIVE
HAMDEN, CT 06517-
HAMDEN, CT 06517-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Toxicogenomics of Hepatotoxicity in Monkeys
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Matthew S. Lawrence
Award Amount:
$249,123.00
Abstract:
DESCRIPTION (provided by applicant):
SBIR Phase I Research:
This proposal aims to examine the predictive utility of an in vivo primate toxicogenomic model of human hepatotoxicity. Hepatotoxicity is the most significant and common adverse drug reaction. A central challenge to pharmaceutical… More
Genomic markers of environmental toxins for Parkinsonism
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Matthew S. Lawrence
Award Amount:
$227,763.00
Abstract:
DESCRIPTION (provided by applicant): Parkinson's disease is a prevalent and devastating neurodegenerative condition of unknown etiology. One prominent hypothesis holds that the selective loss of the nigrostriatal dopaminergic neurons characteristic of the disease results from damage from… More
Toxicogenomics of Hepatotoxicity in Monkeys
Award Year / Program / Phase:
2005 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Matthew S. Lawrence
Award Amount:
$1,126,036.00
Abstract:
DESCRIPTION (provided by applicant):
SBIR Phase I Research:
This proposal aims to examine the predictive utility of an in vivo primate toxicogenomic model of human hepatotoxicity. Hepatotoxicity is the most significant and common adverse drug reaction. A central challenge to pharmaceutical… More
Ultrasound-Mediated Blood-Brain Barrier Permeabilization in Primates
Award Year / Program / Phase:
2006 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Steven R. Gullans
Award Amount:
$208,554.00
Abstract:
DESCRIPTION (provided by applicant): The blood-brain barrier (BBB) represents both a safeguard against the penetration of physiologically harmful substances into the central nervous system (CMS), and a considerable hurdle to the delivery of therapeutic agents. A technology allowing safe, targeted,… More
Ultrasound-Mediated Blood-Brain Barrier Permeabilization in Primates
Award Year / Program / Phase:
2008 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Award Amount:
$1,362,442.00
Abstract:
DESCRIPTION (provided by applicant): The blood-brain barrier (BBB) represents both a safeguard against the penetration of physiologically harmful substances into the central nervous system (CNS), as well as a considerable hurdle to the delivery of therapeu
tic agents. A technology allowing safe,… More
Silencing cardiac-specific microRNAs to prevent pathological remodeling in conges
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Matthew S. Lawrence – 203-498-9706
Award Amount:
$718,304.00
Abstract:
DESCRIPTION (provided by applicant): Heart disease remains the primary cause of morbidity and mortality in the industrialized world and continues to incur costs estimated at 30 billion per year, despite detailed understanding of the mechanisms governing cardiac function and contractility. MicroRNAs… More